Cited 0 times in
Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in de novo diffuse large B-cell lymphoma: a multicenter retrospective study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김유리 | - |
dc.contributor.author | 김진석 | - |
dc.date.accessioned | 2024-04-11T06:37:16Z | - |
dc.date.available | 2024-04-11T06:37:16Z | - |
dc.date.issued | 2024-02 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198839 | - |
dc.description.abstract | Background: Bone marrow (BM) involvement is an indicator of a poor prognosis in diffuse large B-cell lymphoma (DLBCL); however, few studies have evaluated the role of immunoglobulin gene rearrangement (IgR) in detecting BM involvement. Methods: We evaluated the clinical characteristics and treatment outcomes of patients with DLBCL based on histological BM involvement or positive BM IgR using polymerase chain reaction or next-generation sequencing. We also investigated the role of consolidative upfront autologous hematopoietic stem cell transplantation (ASCT) in patients with DLBCL and BM involvement. Results: Among 624 patients, 123 (19.7%) with histological BM involvement and 88 (17.5%) with positive IgR in histologically negative BM had more advanced disease characteristics. Overall (OS) and progression-free (PFS) survival was better for patients with negative BM histology and negative IgR than that in patients with histological BM involvement (P = 0.050 and P < 0.001, respectively) and positive IgR with negative BM histology (P = 0.001 and P = 0.005, respectively). Survival rates did not differ among 82 (13.1%) patients who were treated with upfront ASCT and had histological BM involvement or positive IgR with negative BM histology. The survival outcomes were worse for patients who were not treated with upfront ASCT and for those with histological BM involvement or positive IgR, than for those with negative BM histology and negative IgR. Conclusion: Patients diagnosed with DLBCL and BM involvement based on histology or IgR had aggressive clinical features and poor survival. Upfront ASCT mitigated poor prognosis due to BM involvement. Copyright © 2024 Kim, Shin, Yhim, Yang, Park, Lee, Lee, Do, Mun, Kim and Kim. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Frontiers Research Foundation | - |
dc.relation.isPartOf | FRONTIERS IN ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in de novo diffuse large B-cell lymphoma: a multicenter retrospective study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yu Ri Kim | - |
dc.contributor.googleauthor | Ho Jin Shin | - |
dc.contributor.googleauthor | Ho-Young Yhim | - |
dc.contributor.googleauthor | Deok-Hwan Yang | - |
dc.contributor.googleauthor | Yong Park | - |
dc.contributor.googleauthor | Ji Hyun Lee | - |
dc.contributor.googleauthor | Won-Sik Lee | - |
dc.contributor.googleauthor | Young Rok Do | - |
dc.contributor.googleauthor | Yeung-Chul Mun | - |
dc.contributor.googleauthor | Dae Sik Kim | - |
dc.contributor.googleauthor | Jin Seok Kim | - |
dc.identifier.doi | 10.3389/fonc.2024.1363385 | - |
dc.contributor.localId | A00779 | - |
dc.contributor.localId | A01017 | - |
dc.relation.journalcode | J03512 | - |
dc.identifier.eissn | 2234-943X | - |
dc.identifier.pmid | 38410112 | - |
dc.subject.keyword | bone marrow involvement | - |
dc.subject.keyword | diffuse large B-cell lymphoma | - |
dc.subject.keyword | immunoglobulin gene rearrangement | - |
dc.subject.keyword | progression-free survival | - |
dc.subject.keyword | transplantation | - |
dc.contributor.alternativeName | Kim, Yu Ri | - |
dc.contributor.affiliatedAuthor | 김유리 | - |
dc.contributor.affiliatedAuthor | 김진석 | - |
dc.citation.volume | 14 | - |
dc.citation.startPage | 1363385 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN ONCOLOGY, Vol.14 : 1363385, 2024-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.